<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556372</url>
  </required_header>
  <id_info>
    <org_study_id>JKB-122AIH</org_study_id>
    <nct_id>NCT02556372</nct_id>
  </id_info>
  <brief_title>Liver Test Study of Using JKB-122 in AIH Patients</brief_title>
  <acronym>JKB-122AIH</acronym>
  <official_title>A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiwanJ Pharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiwanJ Pharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks in subjects
      with autoimmune hepatitis (AIH) who have liver enzymes that are 1.25 to 10 times the upper
      limit of normal (ULN) and who have had a failed response to, incomplete response to,
      intolerant to, ineligible to, or unwilling to take current immunosuppressant therapies. The
      dose of JKB-122 will be escalated monthly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks to subjects
      with AIH who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and
      who have had a failed response to, incomplete response to, intolerant to, ineligible to or
      unwilling to take current immunosuppressant therapies. Current immunosuppressant therapy is
      defined as prednisone or other steroids with or without azathioprine. Failed response is
      defined as being non-responsive to or worsening in symptoms (elevated Alanine
      Aminotransferase (ALT)/aspartate aminotransferase (AST) and/or total bilirubin) despite
      compliance with the standard of care (SOC) over a 6 months period. Incomplete response is
      defined as lack of a sustained normalization of elevated ALT/AST to current standard of care
      (SOC) for at least 6 months. &quot;Refractory&quot; to the current therapy includes patients who had a
      failed response to, or incomplete response to the current therapy.

      Subjects will be at least 18 years of age, either male or female and will have been on
      therapy for AIH and have not had a normalization of ALT with the current therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in ALT in AIH subjects given daily doses of JKB-122</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess changes in ALT in AIH subjects given daily doses of JKB-122</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>JKB-122</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JKB-122</intervention_name>
    <description>Orally administered capsules of JKB-122 which will be taken once daily with dose escalation</description>
    <arm_group_label>JKB-122</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has definite or probable AIH diagnosis.

          -  Has had a liver biopsy or Fibroscan™ within 3 years and the severity of hepatic
             dysfunction is limited to the following:

               -  Metavir Stage 0 to stage 3 fibrosis (according to liver biopsy) or Fibroscan™
                  results

               -  ALT and AST values not exceeding 10x ULN

               -  Normal bilirubin and prothrombin time (PT/INR)

          -  Has elevated liver test results (ALT) at least 1.25 x ULN and not exceeding 10 x ULN
             at baseline.

          -  Has had a failed response, incomplete response, intolerant, ineligible or unwilling to
             take current immunosuppressive therapies. Current immunosuppressive therapy is defined
             as prednisone or other steroids with or without azathioprine.

        Exclusion Criteria:

          -  Has history of allergy to JKB-122 or related compounds

          -  Has human immunodeficiency virus (HIV) or is hepatitis B virus or hepatitis C virus
             (HCV) positive

          -  Has positive urine drug screen at Screening

          -  Has been diagnosed with other overlapping liver diseases such as primary biliary
             cirrhosis (PBC) or primary sclerosing cholangitis (PSC)

          -  Is currently consuming alcoholic drinks greater than 25g/day and within 3 months prior
             to the first screening visit.

          -  Is being treated with any prescription narcotic drug (including transdermal delivery
             systems)

          -  Concurrent medications within 30 days prior to screening:

               -  Opioids

               -  Thioridazine

               -  Silymarin and related medications

               -  Potentially hepatotoxic drugs

          -  Has a known or suspected central nervous system disorder that may predispose to
             seizures or lower the seizure threshold

          -  Has unstable and uncontrollable hypertension (&gt;180/110 mmHg) or a blood pressure
             reading at baseline of 150/90 mmHg on 2 occasions separated by a 30 minute interval

          -  Is currently receiving dietary supplements other than a multivitamin to treat AIH

          -  Has received other investigational agents within 90 days prior to the first screening
             visit

          -  Has impaired renal function

          -  Has malignancy.

          -  If female, pregnant or lactating

          -  Has history of gastroesophageal varices, ascites, hepatic encephalopathy,
             hepatocellular carcinoma, and s/p liver transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jason Lai, Ph.D.</last_name>
    <phone>+88636587721</phone>
    <phone_ext>311</phone_ext>
    <email>jasonlai@taiwanj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruane Clinical Research Group, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dani Ain</last_name>
      <phone>323-954-0400</phone>
      <phone_ext>236</phone_ext>
      <email>dain@ruanemedical.com</email>
    </contact>
    <investigator>
      <last_name>Peter Ruane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center - Ticon 1</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Dhaliwal</last_name>
      <phone>916-734-8696</phone>
      <email>sandhaliwal@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Bowlus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kidist K Yimam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Hepatology Research at CTRB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0272</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Horne</last_name>
      <phone>352-273-9464</phone>
      <email>patrick.horne@medicine.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Gunnett</last_name>
      <phone>1-352-273-9470</phone>
      <email>amy.gunnett@medicine.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Morelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Sipich</last_name>
      <phone>312-694-1293</phone>
      <email>k-sipich@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Flamm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Weber</last_name>
      <phone>317-278-3584</phone>
      <email>reginaw@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Lammert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredric Regenstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pratt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mekdes Mersha</last_name>
      <phone>212-241-0493</phone>
      <email>mekdes.mersha@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Odin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loranda Ross</last_name>
      <phone>919-970-1724</phone>
      <email>loranda.ross@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Muir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chavez Beatriz</last_name>
      <phone>214-947-4446</phone>
      <email>BeatrizChavez@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Parvez Mantry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Liver Therapies, Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Lee</last_name>
      <phone>832-355-8708</phone>
      <email>jlee@sleh.com</email>
    </contact>
    <investigator>
      <last_name>John Vierling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Angueira</last_name>
      <phone>210-253-3426</phone>
      <email>cangueira@txliver.com</email>
    </contact>
    <investigator>
      <last_name>Eric Lawitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taxes Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center - Organ Transplant and Liver Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cardona Gonzale</last_name>
      <phone>1-206-386-3201</phone>
      <email>Maria.CardonaGonzalez@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Erik Ness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee McKoin</last_name>
      <email>mckoin@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Landis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>March 31, 2018</last_update_submitted>
  <last_update_submitted_qc>March 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIH</keyword>
  <keyword>JKB-122</keyword>
  <keyword>autoimmune</keyword>
  <keyword>hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

